Contact
Contact
We believe in the potential of iPSC as an unlimited source for next-generation ATMPs, building the French National Bank of GMP iPSC to answer unmet medical needs.
A single national bank reduces cost, logistics and redundancy, and increases the chance of finding rare HLA-matched donors for every patient who needs one.
Every line is held to a high standard of quality control and ethical application, from donor consent to clinical release.
CITHERA is developing the national bank of clinical-grade pluripotent stem cells and new cellular biomedicines to fight cancer. A center of the University of Paris-Saclay, Inserm and the University of Évry at Genopole, directed by Professor Annelise Bennaceur Griscelli and attached to INSERM unit UA09 "Malignant and Therapeutic Stem Cell Models," led by Professor Ali Turhan in Villejuif.
iPSC Platform
From the derivation of the first ESC lines in 2006 to iPSC in 2008, CITHERA coordinates the INGESTEM infrastructure and was named Industrial Integrator by the government's "Grand Défi" recovery-plan innovation council.
Drag the slider to see, in a simplified illustrative model, how the number of banked HLA-homozygous lines could influence theoretical patient compatibility.
Biologists, quality engineers, GMP specialists: join a team building a one-of-a-kind national infrastructure at Genopole, France.
See open positions